Form 4: Anika Therapeutics Director Joseph H. Capper Reports Stock Transaction

Director Joseph H. Capper reports acquisition and disposal of Anika Therapeutics stock on July 9, 2024, according to a Form 4 filing.

Summary

• On July 9, 2024, Joseph H. Capper, a director of Anika Therapeutics, Inc., engaged in a transaction involving the company's common stock.
• Capper acquired 5,771 shares of common stock and disposed of 6,239 shares.
• Following the reported transaction, Capper beneficially owns 6,239 shares of Anika Therapeutics common stock.
• The acquisition involved restricted stock units (RSUs), each representing the contingent right to receive one share of the company's common stock.
• The RSUs vest in full on the earlier of the 2025 annual meeting of the company's stockholders or July 9, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating neutral sentiment. It simply reports a transaction.

Future Outlook

The RSUs vest in full on the earlier of the 2025 annual meeting of the company's stockholders or July 9, 2025.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency to investors regarding the trading activities of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider trading activity.

Key Dates